Chronic Kidney Disease Reversal Medication Announces Promising Results

 © ALL CREDIT TO THEIR RESPECTIVE OWNERS.

© ALL CREDIT TO THEIR RESPECTIVE OWNERS.

Bardoxolone Methyl is a new medication that is being explored to help stop kidney decline and in some cases improve Kidney Function. While anecdotal (personal account) testimonials have suggested that the medication works well for patients, Reata Pharmaceuticals, Inc. is set to make an official announcement that could offer a promising outlook for many patients nearing Dialysis and perhaps existing patients.

Recommended Reading: Breakthrough Medication Reversing Kidney Decline To Help Limit Or Avoid Dialysis And Kidney Transplant

FPWFall.jpg

Reata Pharmaceuticals, Inc. (a clinical-stage biopharmaceutical company) announced positive, final results from the Chronic Kidney Disease Phase II Human Trails for Bardoxolone Methyl. Bardoxolone Methyl, formerly known as RTA 402, is an oral therapy that works by reducing inflammation and oxidative stress and restoring the activity of mitochondria (the cells’ powerhouses), potentially improving Kidney Function.

Recommended Reading: Benadryl And Other Common Chronic Kidney Disease Medications May Increase Risk Of Alzheimer's

Reata is currently recruiting participants for Phase 3 of the Human Trials. The trial’s primary goal appears to be to increase in Kidney Function using Bardoxolone Methyl. If you would like more information and to be kept up-to-date, then input your information below. Also, join KidneyBuzz CONNECT for more insights and the latest about Human Trials for this breakthrough and others (click here):

Name *
Name
Phone *
Phone
Would you like to be kept up-to-date about information related to Bardoxolone Methyl? *

Patients who have taken part in Human Trials for the potential breakthrough medication have experienced "significant improvement in Kidney Function from baseline" even after a four-week withdrawal, suggested Alport Syndrome News. The most commonly reported adverse event was mild to moderate muscle spasms, with no evidence of muscle toxicity. At the time of the analysis, no treatment-related adverse events were observed, and no patient had stopped treatment.

Recommended Reading: Chronic Kidney Disease Patients' Current Medication Regimens "Probably Too Low"

These findings showed that “Bardoxolone Methyl was generally well tolerated and produced improvements in kidney function that were sustained for up to one year and remained significantly above baseline following treatment withdrawal,” the researchers wrote. Will similar findings occur in patients who are currently on Dialysis? The answer: We do not know yet, but hope to find out.

Recommended Reading: The Effects Of Medication "Almost All" CKD Patients Take Are Causing Dire Unintended Effects

KidneyBuzz.com will continue to keep you updated about the latest possible breakthroughs in the Chronic Kidney Disease Community. Would you try the new medication Bardoxolone Methyl? Why or why not? Share your thoughts and insights with the over 80,000 Friends who have liked KidneyBuzz.com on Facebook (click here). Also, follow the over 250,000+ monthly viewers who visit KidneyBuzz.com regularly for the latest daily news and information which teach those with Chronic Kidney Disease, Dialysis, Kidney Transplant, Diabetes, and Hypertension how to better manage and improve their lives. Erica Ashley Jenkins (Dialysis Nurse) said, "Hello I just wanted to let you know I work in a dialysis clinic and over half of our clinic reads this page, we enjoy everything you put on and love to have new information. My patients are very grateful."

Most Popular Stories: